EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische Studie

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation

Arno Furquim d'Almeida iD, Axelle Vanderlinden, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Sersté, Mathieu Struyve, Baro Deressa, Dirk Sprengers, Marie de Vos, Jos Callens, Bao Shihao, Hendrik Reynaert und 18 weitere

Alimentary Pharmacology & Therapeutics · 2026-02 · 63 (3) · 352-361

DOI: 10.1111/apt.70465 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 19.11.2025. Verfasst von Arno Furquim d'Almeida und 29 weiteren Autor:innen. Beteiligte Einrichtung: Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, Hepatitis B, Chronic, Nucleosides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nucleos(t)ide analogue (NUC) cessation can induce a functional cure in chronic hepatitis B virus (HBV) infections, but severe post‐cessation virologic relapses (SVRel) and severe biochemical flares (SBF) frequently occur.

Aims

To identify predictive biomarkers for patients at highest risk for SVRel and SBF.

Methods

In the multicentre prospective COIN‐B trial, start‐of‐treatment HBeAg‐negative, long‐term virologically suppressed patients without advanced fibrosis are followed up for 72 weeks after NUC cessation. We performed a predefined exploratory analysis of the associations between HBV genotype, or end‐of‐treatment (EOT) biomarkers (HBcrAg, HBV RNA, HBsAg, and anti‐HBc IgG) and SVRel (HBV DNA > 5 log IU/mL) or SBF (ALT > 10× ULN) within 48 weeks post‐cessation.

Results

Of 91 recruited patients, 85 completed 48 weeks of follow‐up. SVRel and SBF occurred in 36 (42.4%) and 21 (24.7%) patients, respectively. Genotypes C, D, and E were associated with higher relapse and flare rates, whereas none of the 18 genotype A patients developed SBF. In multivariate analysis, SVRel was independently associated with detectable HBcrAg (aOR 3.93, p = 0.01), and SBF with non‐A genotype (aOR 19.03, p = 0.018), detectable HBV RNA (aOR 7.84, p = 0.005), and lower anti‐HBc IgG levels (aOR 0.31, p = 0.016). A risk stratification tool, the COBRA score, was developed incorporating HBcrAg, HBV RNA, and anti‐HBc IgG. A score ≥ 2 identified patients at increased risk, with 80.0% sensitivity and 90.7% NPV for SBF.

Conclusions

HBV genotype and EOT biomarkers, including HBcrAg, HBV RNA, and anti‐HBc IgG predict SVRel and SBF following NUC cessation. The COBRA score enables pragmatic, individualised risk stratification. Trial Registration ClinicalTrials.gov identifier: NCT04779970, EudraCT: 2021‐001003‐32

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B virusHepatitis B, ChronicNucleosidesAdultFemaleHumansMaleMiddle AgedBiomarkersDNA, ViralGenotypeHepatitis B e AntigensProspective StudiesRecurrenceRNA, Viral

Stichwörter der Autor:innen

antiviral agentsflareshepatitis B virusnucleosideswithholding treatment

Substanzen

Antiviral AgentsBiomarkersDNA, ViralHepatitis B e AntigensNucleosidesRNA, Viral

Autor:innen und Institutionen

  • Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
  • Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
  • Department of Gastroenterology, Ziekenhuis aan de Stroom, Antwerp, Belgium.
  • Department of Hepato-Gastroenterology, CHU Saint-Pierre, Brussels, Belgium.
  • Department of Gastroenterology, Ziekenhuis Oost-Limburg, Genk, Belgium.
  • Department of Gastroenterology, CHU Brugmann, Brussels, Belgium.

ORCID-Profile: Arno Furquim d'Almeida, Thomas Vanwolleghem

Förderung

  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Furquim d'Almeida, A., Vanderlinden, A., Bourgeois, S., Mulkay, J. P., Sersté, T., Struyve, M., Deressa, B., Sprengers, D., de Vos, M., Callens, J., Shihao, B., Reynaert, H., Deltenre, P., Janssens, F., Negrin-Dastis, S., Stärkel, P., Orlent, H., Van Roey, G., Verhelst, X., …, & Vanwolleghem, T. (2026). Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation. Alimentary Pharmacology & Therapeutics, 63(3), 352-361. https://doi.org/10.1111/apt.70465

Vancouver

Furquim d'Almeida A, Vanderlinden A, Bourgeois S, Mulkay JP, Sersté T, Struyve M, et al. Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation. Alimentary Pharmacology & Therapeutics. 2026;63(3):352-361. doi:10.1111/apt.70465

BibTeX
@article{FurquimdAlmeida2026,
  author = {Furquim d'Almeida, Arno and Vanderlinden, Axelle and Bourgeois, Stefan and Mulkay, Jean-Pierre and Sersté, Thomas and Struyve, Mathieu and Deressa, Baro and Sprengers, Dirk and de Vos, Marie and Callens, Jos and Shihao, Bao and Reynaert, Hendrik and Deltenre, Pierre and Janssens, Filip and Negrin-Dastis, Sergio and Stärkel, Peter and Orlent, Hans and Van Roey, Guy and Verhelst, Xavier and Moreno, Christophe and Delwaide, Jean and Van Steenkiste, Christophe and Verlinden, Wim and Colle, Isabelle and Plissonnier, Marie-Laure and Mukadi, Benoît Kabamba and Testoni, Barbara and Zoulim, Fabien and Matheeussen, Veerle and Vanwolleghem, Thomas},
  title = {Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {3},
  pages = {352--361},
  doi = {10.1111/apt.70465}
}
Kostenlos starten →